AuRx to begin a Phase I/II in Mexico

AuRx (Baltimore, Md.) will begin a 64-patient Phase I/II trial of its HSV-2 recombinant herpes theracine in mid-May. The theracine is being developed to prevent recurrences of genital herpes. ...